Michael S. Abrams its chief financial officer.
In alignment with the company’s succession plan, Abrams joins Arch’s financial team in the role previously held by Richard Davis. Davis will remain with the company during a transition period, which will end on June 30, after which he will support the company in a consulting role through Dec. 31.
Abrams has more than 25 years of experience as a chief financial officer to numerous public and private companies; principal investor; investment banker; merchant banker; strategic and financial adviser; and board member. His capabilities span a broad range of activities with a particular expertise in the areas of operational management, complex financial engineering, financial advisory and capital markets strategy primarily for companies in the technology and healthcare sectors.
俄罗斯和中国高校学生为何容易抑郁? sputniknews.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sputniknews.cn Daily Mail and Mail on Sunday newspapers.
Paul Brassil of
Medfield has joined the company as senior vice president/chief information officer and will oversee PCU’s information technology and digital innovation efforts.
Brassil has more than 25 years of experience in the information technology leadership field with entities such as Commonwealth Medicine (a division of UMass Medical School), the Federal Reserve Bank of Boston, EMC Corp. and Siemens IT Solutions and Services Inc.
He holds an MS in computer information systems from Bentley University in
Waltham and a BA in Business Administration from Bridgewater State University.
Brassil s community involvement spans initiatives focused on workforce development and industry leadership serving as a member of the Tech Hire Advisory Group of Boston’s Private Industry Council (comprised of Boston CIOs developing summer intern programs for low/moderate income students in the Boston Public Schools); an adviser for Fintech Women (helping women in banking/finance/fintech a
Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients greensburgdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greensburgdailynews.com Daily Mail and Mail on Sunday newspapers.
(AUSTIN, Texas) NEWS: Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure,” to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
“The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer’s disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease,” said Christian Drape